5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

Catalog No. :
ACSWTO352
CAS No. :
1062174-44-0
Molecular Formula :
C14H20BNO2
Molecular Weight :
245.13

IUPAC Name:5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$122.00Login to see priceIn stockInquiry
5g98%$555.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline
IUPAC Name5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline
MDL No.MFCD16995801
Molecular FormulaC14H20BNO2
Molecular Weight245.13
SMILESCC1(C)C(C)(C)OB(C2=CC3=C(NCC3)C=C2)O1
InChI KeyZYOHYGQNRQMVMG-UHFFFAOYSA-N
SynonymAM86268 | 1062174-44-0 | SCHEMBL12470951 | Indoline-5-boronic acid pinacol ester | MFCD16995801 | 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-indole | EN300-6764480 | 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-indole | ZYOHY
CAS No.1062174-44-0
PubChem CID56776842

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACSWTO352 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMLYA328 route compound structure diagram
    ACMLYA32822190-33-6 In Stock
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACSWTO352 route product structure diagram
    ACSWTO3521062174-44-0 In Stock
Inquiry

2. ACSWTO352 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSVLI192 route compound structure diagram
    ACSVLI192837392-67-3 In Stock
  2. Then
  3. ACSWTO352 route product structure diagram
    ACSWTO3521062174-44-0 In Stock
Inquiry

Comments (0)